摘要
Antimicrobial resistance is a global public health threat,and the World Health Organization(WHO)has announced a priority list of the most threatening pathogens against which novel antibiotics need to be developed.The discovery and introduction of novel antibiotics are time-consuming and expensive.According to WHO’s report of antibacterial agents in clinical development,only 18 novel antibiotics have been approved since 2014.Therefore,novel antibiotics are critically needed.Artificial intelligence(AI)has been rapidly applied to drug development since its recent technical breakthrough and has dramatically improved the efficiency of the discovery of novel antibiotics.Here,we first summarized recently marketed novel antibiotics,and antibiotic candidates in clinical development.In addition,we systematically reviewed the involvement of AI in antibacterial drug development and utilization,including small molecules,antimicrobial peptides,phage therapy,essential oils,as well as resistance mechanism prediction,and antibiotic stewardship.
基金
supported by the National Natural Science Foundation of China(32300157)
the Shanghai Municipal Science and Technology Commission(19411964900)
the Major Research and Development Project of Innovative Drugs,Ministry of Science and Technology of China(2017ZX09304005)
the Wellcome Trust.
作者简介
Guang-Yu Liu,contributed equally to this work;Dan Yu,contributed equally to this work;Correspondence:Christoph Tang,christoph.tang@path.ox.ac.uk;Correspondence:Xiao-Fen Liu,xiaofenliu@fudan.edu.cn。
